Posts

Claris collects $118M to take eye drop into pivotal testing next year

on

Crystalys Raises $130M Series B to Advance Gout Drug Dotinurad Through Phase 3

on

Ollin nets $330M to fund Phase 3 trials of Vabysmo challenger from China (OLN324)

on

Osanni Bio raises $190M to advance ophthalmology and cardiology pipeline, including dry AMD candidate

on

Nura Bio Raises $73.8M Series B to Advance SARM1 Inhibitors for Neurodegeneration

on

City Therapeutics raises $99.5M to advance three RNAi programs and its next‑generation platform

on

Create Medicines raises $122M to advance in vivo CAR-T programs

on

Novartis-Backed Sidewinder Therapeutics Raises $137M Series B for Bispecific ADCs Targeting Hard-to-Treat Tumors

on

Ambrosia Raises $100M Series B to Develop Next-Generation Small Molecule GLP-1s

on

Pinnacle Medicines Secures $89M Series B Funding for Oral Peptide Pipeline

on

Crossbow Therapeutics Raises $77M Series B to Advance T-Bolt T-Cell Engager Therapies

on

CHARM Therapeutics Raises $80M in Oversubscribed Series B for Next-Gen Menin Inhibitor in AML

on

Galux Raises $29M Series B for AI Protein Design

on

Exciva Raises €51M ($59M) Series B to Fund Phase 2 Trial of Deraphan for Alzheimer's Agitation

on

Brian Armstrongs NewLimit raises a $130M Series B, laying out road map for anti-aging drugs

on

Curevo Secures $110M for Advanced Shingles Vaccine Development

on

Latigo saddles up with $150M to spur non-opioid pain drugs through the clinic

on